[Phase II study of FF-705 by Clinical Cooperative Study Group].
Clinical efficacy of new fluorouridine derivative, FF-705, was studied in 108 patients with advanced malignant tumors. Partial responses were observed in 8 of 61 evaluable cases (13.1%): 4 of 9 patients with breast cancer, 1 of 19 patients with gastric cancer, 1 of 15 patients with lung cancer, 1 of 3 patients with kidney cancer and 1 of 1 patient with pancreas cancer. In the analysis of adverse effects of FF-705, gastrointestinal toxicity was major toxicity. Especially, diarrhea was observed in 41 of 108 patients (38.0%) within a total dose of 10 g shortly after drug administration.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy; D002214:Capsules; D003110:Colonic Neoplasms / Q000188:drug therapy; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005467:Floxuridine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D013274:Stomach Neoplasms / Q000188:drug therapy
D002214:Capsules; D005467:Floxuridine; C040250:2'-deoxy-3',5'-di-O-acetyl-5-fluoro-3-(3-methylbenzoyl)uridine